Scarica l'app Stockscreener
23.14
0.00%
0.00
Precedente Chiudi:
$23.14
Aprire:
$23.34
Volume 24 ore:
699.01K
Relative Volume:
1.09
Capitalizzazione di mercato:
$1.70B
Reddito:
$81.26M
Utile/perdita netta:
$-102.66M
Rapporto P/E:
-16.92
EPS:
-1.3678
Flusso di cassa netto:
$-77.62M
1 W Prestazione:
+0.76%
1M Prestazione:
-5.28%
6M Prestazione:
-12.35%
1 anno Prestazione:
+83.21%
Intervallo 1D:
$22.65
$23.59
Intervallo di 1 settimana:
$22.14
$23.59
Portata 52W:
$11.51
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
23.14 | 1.70B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Why Zymeworks’ zanidatamab is drawing fresh attention from cancer specialists - AD HOC NEWS
Zymeworks stock rises on Gandeeva cryo-EM partnership - Investing.com
Gandeeva and Zymeworks partner on antibody drug discovery By Investing.com - Investing.com India
Gandeeva and Zymeworks partner on antibody drug discovery - Investing.com
Zymeworks stock rises on Gandeeva cryo-EM partnership By Investing.com - Investing.com Australia
Zymeworks partner maps a tiny antibody target at 2.6 Å - Stock Titan
Why Zymeworks’ zanidatamab path is all about the bispecific details - AD HOC NEWS
Zymeworks Inc (ZYME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zymeworks Inc (ZYME) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zymeworks Inc (ZYME) Institutional Confidence - TradingKey
Zymeworks Inc (ZYME) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zymeworks Inc (ZYME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zymeworks Inc Stock (US98986T1088): Quarterly earnings keep biotech name in focus - AD HOC NEWS
Citizens reiterates Zymeworks stock rating on ADC pipeline progress - Investing.com
Citizens reiterates Zymeworks stock rating on ADC pipeline progress By Investing.com - Investing.com Canada
Did Strong ZW191 Phase 1 Data in Resistant Gynecologic Cancers Just Shift Zymeworks' (ZYME) Investment Narrative? - Sahm
Zymeworks (ZYME) Unveils Promising Phase 1 Data for ZW191 in Ova - GuruFocus
Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa
Zymeworks reports phase 1 trial results for ovarian cancer drug - Investing.com
Zymeworks Inc. Reports Promising Phase 1 Results for ZW191 in Platinum-Resistant Ovarian Cancer Patients - Quiver Quantitative
Ovarian cancer study: 78.6% response in one group on Zymeworks' ZW191 - Stock Titan
Zymeworks Inc. (ZYME) reports Q1 loss, misses revenue estimates - MSN
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and Zymeworks (ZYME) - The Globe and Mail
ZYME Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues R&D InvestmentQuarterly Financial Update - newsline.com
Truist assumes Zymeworks stock coverage with buy rating on royalty platform - Investing.com UK
Truist assumes Zymeworks stock coverage with buy rating on royalty platform By Investing.com - Investing.com India
Zymeworks stock drops 4.22% as Zymeworks Inc posts National Cancer Survivors Day tribute - Traders Union
Is Zymeworks’ ADC Progress And Buyback Plan Reframing The Investment Case For ZYME? - Sahm
A Look At Zymeworks (ZYME) Valuation After Recent Clinical And Regulatory Milestones - Sahm
Zymeworks stock price target maintained at $46 by H.C. Wainwright - Investing.com UK
Truist Securities initiates coverage of Zymeworks (ZYME) with buy recommendation - MSN
ZYME Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Zymeworks Inc stock (US98986T1088): upcoming Jefferies conference appearance in focus - AD HOC NEWS
ZYME News | ZYMEWORKS INC (NASDAQ:ZYME) - ChartMill
Zymeworks Inc stock (US98985W1080): investor focus on AACR data and sector backdrop - AD HOC NEWS
Zymeworks (ZYME) Shares Slip 2.4%, Testing Support Near $23.55Monthly Profile - thelegaladvocate.com
Zymeworks Inc. (ZYME) Faces Selling Pressure as Shares Dip 2.40% — Key Levels in FocusPut Call Ratio - thelegaladvocate.com
Zymeworks Inc. (ZYME) Edges Higher as Support Holds SteadyTWAP Entry - The Legal Advocate
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? - MSN
Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Zymeworks Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Inc. (ZYME) - Minichart
Breakeven Is Near for Zymeworks Inc. (NASDAQ:ZYME) - Moomoo
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality (ZYME) - Seeking Alpha
Zymeworks authorizes fresh $125M share buyback - MSN
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):